Novartis AG Iptacopan (LNP023) Update Call Transcript
Good morning, and good afternoon, and welcome to the Novartis Iptacopan Update. (Operator Instructions) A recording of this conference call, including the Q&A session, will be available on our website shortly after the call ends. (Operator Instructions) With that, I would like to hand over to Mr. Samir Shah, Head of Investor Head of Investor Relations. Please go ahead, sir.
Thank you very much, and welcome, everybody, and good morning and good afternoon as well. Thank you so much for taking the time to participate in this iptacopan update. People are a little surprised as to why we're doing an update on a single molecule. But as you'll see, and you probably know from having read some of the slides, it's because we've got a number of indications for iptacopan and we thought it was a good time around this stage to actually go through in a little more detail the various indications and the way we're trying to develop iptacopan in the 2 therapeutic areas of nephrology and hematology.
It's my great pleasure
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
